logo
logo
AbCellera Biologics Inc.

AbCellera Biologics Inc.

NASDAQ•ABCL
CEO: Dr. Carl L.G. Hansen Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-12-11
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
連絡先情報
2215 Yukon Street, Vancouver, BC, V5Y 0A1, Canada
604-559-9005
www.abcellera.com
時価総額
$948.89M
PER (TTM)
-5.5
19.5
配当利回り
--
52週高値
$6.52
52週安値
$1.89
52週レンジ
28%
順位37Top 34.1%
4.4
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
堅調 • 4.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$8.96M+37.62%
直近4四半期の推移

EPS

-$0.19+11.77%
直近4四半期の推移

フリーCF

-$61.52M+29.30%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth 27% Total revenue reached 30.3M USD for nine months ended September 30, 2025, marking a 27% increase from prior period.
Operating Loss Reduced Loss from operations narrowed by 53.5M USD to (188.5M USD) for the nine months ended September 30, 2025.
Pipeline Molecules Advance Molecules in the clinic increased to 18 as of September 30, 2025, representing 29% growth over the prior period.
Partner Programs Expanding Partner-initiated program starts with downstreams grew 8% to 103 cumulatively, indicating strong partnership pipeline activity.

リスク要因

Continued Operating Losses Expect continued expenditures and operating losses for the foreseeable future; profitability timing remains uncertain, impacting capital needs.
Partner Development Reliance Business success heavily relies on partners successfully developing and commercializing discovered antibodies; this is outside of management control.
Cash Burn and Liquidity Total cash and marketable securities decreased by 129.9M USD since year-end 2024, driven by ongoing research and development cash use.
Intellectual Property Enforcement Failure to maintain broad IP protection or successfully defend against challenges could allow competitors to copy core technology.

見通し

Final Platform Investments On track to complete final large platform investments, including clinical manufacturing facility, during the 2025 fiscal year.
Internal Pipeline Advancement Advanced ABCL688 into IND/CTA-enabling studies; expect IND/CTA submission for this autoimmunity program in 2026.
Sufficient Liquidity Runway Available liquidity expected to meet working capital and CapEx needs for at least the next 36 months based on current plan.

同業比較

売上高 (TTM)

Xeris Biopharma Holdings, Inc.XERS
$266.14M
+42.0%
Arcus Biosciences, Inc.RCUS
$240.00M
-8.7%
Viridian Therapeutics, Inc.VRDN
$70.79M
+23340.1%

粗利益率 (最新四半期)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Janux Therapeutics, Inc.JANX
95.0%
-5.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CELC$4.97B-29.5-179.0%67.3%
EWTX$3.18B-20.2-30.9%0.7%
VERA$3.00B-10.9-50.9%14.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
21.0%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月24日
|
EPS:-$0.16
|
売上高:$6.31M
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $8.96M+37.6%
    |
    EPS: $-0.19+11.8%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $17.08M+133.3%
    |
    EPS: $-0.12-7.7%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $4.24M-57.5%
    |
    EPS: $-0.15+7.1%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $28.83M-24.2%
    |
    EPS: $-0.55-7.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月4日|
    売上高: $6.51M-1.4%
    |
    EPS: $-0.17+70.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $7.32M-27.2%
    |
    EPS: $-0.13+18.2%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $9.95M-18.4%
    |
    EPS: $-0.14+0.0%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月20日|
    売上高: $38.03M-92.2%
    |
    EPS: $-0.51-191.1%
    予想を下回る